ReNeuron gets good results in artery disease tests
LONDON (Reuters) – ReNeuron reported on Monday positive results in preclinical trials of its lead line of stem cells in peripheral arterial disease (PAD).
PAD affects at least one in 20 people over the age of 55 and is commonly associated with other conditions such as diabetes, obesity and stroke.
In rodent tests the cells were seen to generate “significant” recovery of blood flow in an affected limb, ReNeuron said.
“This work will … give us a significant advantage as we look to move this cell line forward to the clinic as a non patient-specific therapeutic candidate for peripheral arterial disease,” said Chief Scientific Officer John Sinden in a statement.
PAD and retinal diseases are key targets for the company alongside strokes for which the company got UK approval to start human trials in January.
Stem cells operate as “master cells” in the body that scientists hope to coax into repairing damaged tissue, but getting regulators to approve tests on humans has proved difficult because the technology is so new.
[Read the full article here]Related News:
Stem Cell Treatment For Peripheral Artery Disease May Be Guided By Seaweed And Fireflies Brew
Seaweed And Fireflies Brew May Guide Stem Cell Treatment For Peripheral Artery Disease
Stem cell therapy promising for leg artery disease